Frequency of cytochrome P4502C9 mutant alleles in a Korean population

被引:114
作者
Yoon, YR
Shon, JH
Kim, MK
Lim, YC
Lee, HR
Park, JY
Cha, IJ
Shin, JG
机构
[1] Inje Univ, Coll Med, Clin Pharmacol Ctr, Dept Pharmacol, Pusan 614735, South Korea
[2] Pusan Paik Hosp, Clin Pharmacol Ctr, Pusan, South Korea
[3] Chonnam Natl Univ, Coll Med, Dept Pharmacol, Pusan, South Korea
关键词
CYP2C9; genotype; Korean;
D O I
10.1046/j.1365-2125.2001.00340.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Aims To determine the frequencies of CYP2C9 variants in the Korean population and compare them with the frequencies in other ethnic populations. Methods Genotyping of CYP2C9(star)2 and CYPC9 star3 allelic variants was carried out in 574 Korean subjects by PCR and restriction fragment length pattern analysis. Results Thirteen of 574 subjects (2.3%) were heterozygous for CYP2C9 star3 (Ile(359)Leu), but no subjects with a CYP2C9 star2 allele or homozygous for CYP2C9 star3 were identified. The allele frequency of CYP2C9 star3 in Korean subjects (0.0113, 95% CI 0.0066-0.0193) was similar to that of-other East Asian populations, but was considerably lower than that of Caucasian populations. Conclusions CYP2C9 star3 seems to be an allelic variant related to the functional polymorphism of CYP2C9. but this variant is rarely seen among Koreans compared with Caucasians. Routine genotyping of the CYP2C9C star2 allele is considered to be unnecessary in Korean and East Asians, because this allele appears to be extremely rare or absent in these populations.
引用
收藏
页码:277 / 280
页数:4
相关论文
共 13 条
[1]  
ANG SL, 1995, PHARMACOGENETICS, V5, P37
[2]  
Aynacioglu AS, 1999, BRIT J CLIN PHARMACO, V48, P409
[3]   GENERAL METHOD FOR ISOLATION OF HIGH MOLECULAR-WEIGHT DNA FROM EUKARYOTES [J].
BLIN, N ;
STAFFORD, DW .
NUCLEIC ACIDS RESEARCH, 1976, 3 (09) :2303-2308
[4]   Genetic polymorphism of cytochrome P450s, CYP2C19, and CYP2C9 in a Japanese population [J].
Kimura, M ;
Ieiri, I ;
Mamiya, K ;
Urae, F ;
Higuchi, S .
THERAPEUTIC DRUG MONITORING, 1998, 20 (03) :243-247
[5]   Lung cancer risk in relation to the CYP2C9*1/CYP2C9*2 genetic polymorphism among African-Americans and Caucasians in Los Angeles County, California [J].
London, SJ ;
Daly, AK ;
Leathart, JBS ;
Navidi, WC ;
Idle, JR .
PHARMACOGENETICS, 1996, 6 (06) :527-533
[6]   Cytochrome P4502C9: an enzyme of major importance in human drug metabolism [J].
Miners, JO ;
Birkett, DJ .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 45 (06) :525-538
[7]   Genetic analysis of CYP2C9 polymorphism in a Japanese population [J].
Nasu, K ;
Kubota, T ;
Ishizaki, T .
PHARMACOGENETICS, 1997, 7 (05) :405-409
[8]   IMPAIRED (S)-WARFARIN METABOLISM CATALYZED BY THE R144C ALLELIC VARIANT OF CYP2C9 [J].
RETTIE, AE ;
WIENKERS, LC ;
GONZALEZ, FJ ;
TRAGER, WF ;
KORZEKWA, KR .
PHARMACOGENETICS, 1994, 4 (01) :39-42
[9]   Genetic analysis of the human cytochrome P450 CYP2C9 locus [J].
Stubbins, MJ ;
Harries, LW ;
Smith, G ;
Tarbit, MH ;
Wolf, CR .
PHARMACOGENETICS, 1996, 6 (05) :429-439
[10]   The role of the CYP2C9-Leu(359) allelic variant in the tolbutamide polymorphism [J].
SullivanKlose, TH ;
Ghanayem, BI ;
Bell, DA ;
Zhang, ZY ;
Kaminsky, LS ;
Shenfield, GM ;
Miners, JO ;
Birkett, DJ ;
Goldstein, JA .
PHARMACOGENETICS, 1996, 6 (04) :341-349